HOXD13 and breast cancer: A 6 epimarker panel (SFN, P16, hMLH1, HOXD13, PCDHGB7, RASSF1a) discriminated BC and benign cases from controls with 78% sensitivity42 and combinatorial methylation panel comprising GSTP1, RARβ2, RASSF1 and APC detected early-stage tumours with a sensitivity of 33%.